Virtus Biotech Clinical Trials ETF
18 hedge funds and large institutions have $2.84M invested in Virtus Biotech Clinical Trials ETF in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
1,853% more capital inflows, than outflows
Capital inflows: $1.06M | Capital outflows: $54.5K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
13% more funds holding
Funds holding: 16 → 18 (+2)
11.38% more ownership
Funds ownership: 14.39% → 25.77% (+11%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$944K |
| 2 |
Morgan Stanley
New York
|
+$51.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$35.8K |
| 4 |
DI
DAGCO Inc
Westlake,
Ohio
|
+$15.8K |
| 5 |
O'Dell Group
Cincinnati,
Ohio
|
+$2.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$37.6K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$9K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$6.32K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.6K |
BBC Hedge Fund Activity: Q4 2023 in Review
18 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q4 2023, worth a combined $2.84M — up 123% from $1.27M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BBC positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $944K. The largest seller was LPL Financial, cutting an estimated $37.6K.
- 18 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q4 2023, up from 16 in Q3 2023.
- Funds reported $2.84M of Virtus Biotech Clinical Trials ETF stock for Q4 2023, up 123% quarter-over-quarter.
- 4 funds opened new Virtus Biotech Clinical Trials ETF positions in Q4 2023 and 2 closed out, a net change of +2 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q4 2023 was Susquehanna International Group, an estimated $944K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q4 2023 was LPL Financial, an estimated $37.6K sold.
Based on aggregated 13F filings for Q4 2023.